IBRX fundamentals
An in-depth look to ImmunityBio, Inc. operating, investing, and financing activities
IBRX free cash flow for Q1 24 is -108.25 M USD. For 2023, IBRX free cash flow was -397.34 M USD and operating cash flow was -366.76 M USD.
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
0.00
Cash from operating activities
Cash from investing activities
Cash from financing activities
Currency: USD
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
TTM